|
|
| |
CE. It's working everywhere you are
Developing innovative solutions for the laboratory begins with a solid understanding of our customers, their processes and daily challenges. Combined with our state-of-the-art technology and leading-edge science, this knowledge produces total systems solutions that streamline and expedite every step of sample processing – preparation, analysis, result reporting, and data archiving.
|
| |
|
More Info
|
|
|
|
Chiral Analysis
The construction of a chiral environment in capillary electrophoresis is achieved by simply filling the capillary with a buffer containing a chiral additive. Although many chiral selectors have been used, the most comprehensive and effective separation strategies have been achieved with sulfated cyclodextrins. The adjacent graph illustrates the separation of amphetamine enantiomers using this approach, and highlights the degree of enantiomer resolution which may be achieved with these selectors.
|
| |
|
|
Simplified Methods Development
Our chiral methods development strategy uses a family of highly sulfated cyclodextrins that have been developed and formulated to functional specifications for enantiomer analysis, thus ensuring a reliable commercial supply of enantiomer selectors. This methods development strategy uses a single separation with a, b, and g highly sulfated cyclodextrins to resolve acidic, basic neutral, and zwitterionic pharmaceuticals. And by simply reversing the sample introduction to the other side of the capillary, very rapid separations can be generated using only a 10 cm length. The adjacent graph illustrates the rapid analysis of phenylalanine enantiomers in less than one minute.
|
| |
|
|
Genetic Analysis
By simply introducing a polymer into the separation buffer, you can rapidly create a physical gel (entangled polymer network) to provide a size-based separation of nucleic acids. This approach--known as capillary gel electrophoresis (or CGE)--has provided an automated and quantitative replacement of gel electrophoresis for oligonucleotide quality control, RNA purity analysis, plasmid heterogeneity analysis, gene expression studies, and the analysis of DNA/protein interactions. Shown here is the purity analysis of multiple oligonucleotides using a high-throughput mode known as serial injection before analysis (SIBA).
|
| |
|
|
Ultrafast RNA Purity Analysis
Messenger RNA pools are widely used for cDNA library generation, creation of expressed sequence tag (EST) databases, and gene expression profiling. However, the quality of this RNA is an important consideration, as these molecules are highly susceptible to degradation by naturally contaminating RNAses. The P/ACE MDQ with Laser-induced fluorescence (LIF) detection may be used for the unattended processing of total RNA from 96-well plates, followed by automated and quantitative data analysis, with only a 5-minute cycle time per run (3 minutes separation and 2 minutes matrix replacement).
Electropherogram of RNA sample as shown are: (a) RNA 6000 Ladder size standard; (b) Intact total RNA extracted from rice; (c) Degraded total RNA from rice; (d) Intact total RNA from yeast; (e) Intact total RNA from mouse.
|
| |
|
|
Basic Drugs
While the highly polar nature of basic pharmaceuticals makes chromatography complex, CE has the ability to excel at such separations. The graph shows the analysis of 20 basic drugs using low pH, where the capillary surface is essentially neutral and the amine functional groups on the solutes are maximally ionized. The robust nature of this tool and the ruggedness of this particular approach are appropriate for screening protocols used in drug discovery and forensic toxicology.
|
| |
|
|
Ion Analysis
When capillary electrophoresis was introduced, it was seen as a revolutionary technique. Now, it's fulfilling a role as a workhorse in analytical laboratories. In fact, CE should be considered first when dealing with highly polar, charged analytes. It has excelled in the rapid analysis of ions, shown in the graph, and become predominant for impurity analysis of basic and chiral pharmaceuticals.
|
| |
|
|
|
|
|
|
|
|
|
| |
|
